相似文献
1
International conference: progress in vaccination against cancer (PIVAC) 2002, Nottingham, UK.
Cancer Immunol Immunother. 2003 Jun;52(6):403-7. doi: 10.1007/s00262-002-0366-3. Epub 2003 Apr 9.
2
The Twelfth International Conference on Progress in Vaccination Against Cancer (PIVAC 12), Nottingham, UK, 11-13 September 2012: insights into the dynamics of anti-tumour immunity and the development of cancer vaccines.
Cancer Immunol Immunother. 2013 Aug;62(8):1431-7. doi: 10.1007/s00262-013-1440-8. Epub 2013 Jun 14.
3
The fifteenth International Conference on Progress in Vaccination against Cancer (PIVAC-15), 6-8 October 2015, Tübingen, Germany: looking back on 15 years of progress.
Cancer Immunol Immunother. 2017 Feb;66(2):273-279. doi: 10.1007/s00262-016-1888-4. Epub 2016 Aug 24.
4
Cancer vaccination progress.
Trends Mol Med. 2002 Dec;8(12):545-6. doi: 10.1016/s1471-4914(02)02430-9.
5
International conference: progress in vaccination against cancer-2006 (PIVAC 6), Granada, Spain.
Cancer Immunol Immunother. 2007 Aug;56(8):1311-22. doi: 10.1007/s00262-007-0308-1. Epub 2007 Mar 21.
6
Progress in vaccination against cancer (PIVAC) 2002.
Expert Rev Vaccines. 2002 Oct;1(3):261-3. doi: 10.1586/14760584.1.3.261.
7
Progress in vaccination against cancer (PIVAC) 2001, Robinson College, University of Cambridge, UK.
Cancer Immunol Immunother. 2002 Mar;51(1):58-61. doi: 10.1007/s00262-001-0252-4. Epub 2002 Jan 10.
8
5th European conference on Progress in Vaccination Against Cancer. 20-21 September 2005, Athens, Greece.
Expert Opin Biol Ther. 2005 Dec;5(12):1647-51. doi: 10.1517/14712598.5.12.1647.
9
Fifth European progress in vaccination against cancer conference, PIVAC 5.
Cancer Immunol Immunother. 2006 Jul;55(7):884-90. doi: 10.1007/s00262-005-0120-8. Epub 2006 Jan 12.
10
The Fourteenth International Conference on Progress in Vaccination Against Cancer (PIVAC-14), September 24-26, 2014, Rome, Italy: rethinking anti-tumor vaccines in a new era of cancer immunotherapy.
Cancer Immunol Immunother. 2015 Oct;64(10):1349-56. doi: 10.1007/s00262-015-1676-6. Epub 2015 Mar 12.
引用本文的文献
1
Progress in vaccination against cancer-7: report of the meeting in Stockholm, September 10-11, 2007.
Cancer Immunol Immunother. 2008 Apr;57(4):593-9. doi: 10.1007/s00262-007-0420-2. Epub 2007 Nov 20.
2
International conference: progress in vaccination against cancer-2006 (PIVAC 6), Granada, Spain.
Cancer Immunol Immunother. 2007 Aug;56(8):1311-22. doi: 10.1007/s00262-007-0308-1. Epub 2007 Mar 21.
3
Fifth European progress in vaccination against cancer conference, PIVAC 5.
Cancer Immunol Immunother. 2006 Jul;55(7):884-90. doi: 10.1007/s00262-005-0120-8. Epub 2006 Jan 12.
本文引用的文献
1
Melan-A/MART-1-specific CD8 T cells: from thymus to tumor.
Trends Immunol. 2002 Jul;23(7):325-8. doi: 10.1016/s1471-4906(02)02244-5.
2
Prediction of an HLA-DR-binding peptide derived from Wilms' tumour 1 protein and demonstration of in vitro immunogenicity of WT1(124-138)-pulsed dendritic cells generated according to an optimised protocol.
Cancer Immunol Immunother. 2002 Jul;51(5):271-81. doi: 10.1007/s00262-002-0278-2. Epub 2002 Apr 26.
3
An integrated approach utilizing artificial neural networks and SELDI mass spectrometry for the classification of human tumours and rapid identification of potential biomarkers.
Bioinformatics. 2002 Mar;18(3):395-404. doi: 10.1093/bioinformatics/18.3.395.
4
Tumor regression induced by intratumor therapy with a disabled infectious single cycle (DISC) herpes simplex virus (HSV) vector, DISC/HSV/murine granulocyte-macrophage colony-stimulating factor, correlates with antigen-specific adaptive immunity.
J Immunol. 2002 Apr 1;168(7):3512-9. doi: 10.4049/jimmunol.168.7.3512.
5
Progress in vaccination against cancer (PIVAC) 2001, Robinson College, University of Cambridge, UK.
Cancer Immunol Immunother. 2002 Mar;51(1):58-61. doi: 10.1007/s00262-001-0252-4. Epub 2002 Jan 10.
6
mRNA-based electrotransfection of human dendritic cells and induction of cytotoxic T lymphocyte responses against the telomerase catalytic subunit (hTERT).
J Immunol Methods. 2002 Jan 1;259(1-2):191-203. doi: 10.1016/s0022-1759(01)00506-3.
7
Direct evidence that leukemic cells present HLA-associated immunogenic peptides derived from the BCR-ABL b3a2 fusion protein.
Blood. 2001 Nov 15;98(10):2887-93. doi: 10.1182/blood.v98.10.2887.
8
Expression of the serpin serine protease inhibitor 6 protects dendritic cells from cytotoxic T lymphocyte-induced apoptosis: differential modulation by T helper type 1 and type 2 cells.
J Exp Med. 2001 Sep 3;194(5):657-67. doi: 10.1084/jem.194.5.657.
9
Inhibition of activated/memory (CD45RO(+)) T cells by oxidative stress associated with block of NF-kappaB activation.
J Immunol. 2001 Sep 1;167(5):2595-601. doi: 10.4049/jimmunol.167.5.2595.
10
Human anti-idiotypic antibodies can be good immunogens as they target FC receptors on antigen-presenting cells allowing efficient stimulation of both helper and cytotoxic T-cell responses.
Int J Cancer. 2001 May 1;92(3):414-20. doi: 10.1002/ijc.1194.
Zotero 插件